Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Olaparib for Relapsed/Refractory PTCL
NCT06160843Phase 2Recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Jul 2024
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in peripheral T-cell lymphoma (PTCL), sponsored by National Cancer Centre Singapore. Started Jul 2024; status: recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06160843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160843.